Vascular Biogenics Ltd. (VBLT) Shares Down 4.5%
Vascular Biogenics Ltd. (NASDAQ:VBLT) shares were down 4.5% during mid-day trading on Thursday . The stock traded as low as $4.15 and last traded at $4.20, with a volume of 235,307 shares changing hands. The stock had previously closed at $4.40.
Several research analysts have recently issued reports on VBLT shares. Roth Capital reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Vascular Biogenics in a research note on Thursday, June 9th. HC Wainwright started coverage on Vascular Biogenics in a research note on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Vascular Biogenics in a research note on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Vascular Biogenics presently has an average rating of “Buy” and a consensus price target of $16.50.
The company’s 50 day moving average is $4.23 and its 200 day moving average is $3.68. The company’s market cap is $98.44 million.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). On average, equities analysts predict that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.